• Je něco špatně v tomto záznamu ?

Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer

S. Chattopadhyay, G. Zheng, A. Hemminki, A. Försti, K. Sundquist, J. Sundquist, K. Hemminki

. 2020 ; 183 (3) : 488-494. [pub] 20200206

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020160

Grantová podpora
Forskningsrådet om Hälsa, Arbetsliv och Välfärd - International
Helsingin ja Uudenmaan Sairaanhoitopiiri - International
Jane ja Aatos Erkon Säätiö - International
Deutsche Krebshilfe - International
Helsingin Yliopiston Tiedesäätiö - International

BACKGROUND: Patients with squamous cell skin cancer (SCC) have an excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in patients with SCC is not known. OBJECTIVES: To quantify the risk of family history on SPCs in patients with SCC and estimate survival probabilities of patients with SPCs depending on family history. METHODS: With 13 945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios (HRs) were assessed using a multivariable Cox proportional-hazards model. RESULTS: Family history of invasive SCC increased risk of second invasive SCC [RR = 42·92, 95% confidence interval (CI) 33·69-50·32] compared with risk without family history (RR 19·12, 95% CI 17·88-21·08). Family history of any nonskin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC (RRFH = 1·48, 95% CI 1·35-1·61 vs. RRno FH = 1·40, 95% CI 1·32-1·48); significant increases were observed for seven different nonskin cancers. Most results were replicated for in situ SCC. SPC was deleterious for survival irrespective of family history; HR for patients with SPC was 4·28 (95% CI 3·83-4·72) vs. those without SPC (1·04). CONCLUSIONS: Family history of nonskin cancer was associated with approximately a doubling of risk for SPCs in patients with SCC. SPC increases the death rate in patients with SCC 3-4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs. What's already known about this topic? Second primary cancers (SPCs) are frequently diagnosed in patients with invasive and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a link to immune dysfunction. Family history of cancer is a risk factor for practically all first primary cancers but whether it also influences risk of SPCs in patients with SCC is not known. The possible influence of family history on survival in patients with SCC remains to be established. Linked Comment: Youlden and Baade. Br J Dermatol 2020; 183:414-415.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020160
003      
CZ-PrNML
005      
20210830101758.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjd.18809 $2 doi
035    __
$a (PubMed)31853941
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Chattopadhyay, S $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Faculty of Medicine, University of Heidelberg, Heidelberg, Germany
245    10
$a Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer / $c S. Chattopadhyay, G. Zheng, A. Hemminki, A. Försti, K. Sundquist, J. Sundquist, K. Hemminki
520    9_
$a BACKGROUND: Patients with squamous cell skin cancer (SCC) have an excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in patients with SCC is not known. OBJECTIVES: To quantify the risk of family history on SPCs in patients with SCC and estimate survival probabilities of patients with SPCs depending on family history. METHODS: With 13 945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios (HRs) were assessed using a multivariable Cox proportional-hazards model. RESULTS: Family history of invasive SCC increased risk of second invasive SCC [RR = 42·92, 95% confidence interval (CI) 33·69-50·32] compared with risk without family history (RR 19·12, 95% CI 17·88-21·08). Family history of any nonskin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC (RRFH = 1·48, 95% CI 1·35-1·61 vs. RRno FH = 1·40, 95% CI 1·32-1·48); significant increases were observed for seven different nonskin cancers. Most results were replicated for in situ SCC. SPC was deleterious for survival irrespective of family history; HR for patients with SPC was 4·28 (95% CI 3·83-4·72) vs. those without SPC (1·04). CONCLUSIONS: Family history of nonskin cancer was associated with approximately a doubling of risk for SPCs in patients with SCC. SPC increases the death rate in patients with SCC 3-4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs. What's already known about this topic? Second primary cancers (SPCs) are frequently diagnosed in patients with invasive and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a link to immune dysfunction. Family history of cancer is a risk factor for practically all first primary cancers but whether it also influences risk of SPCs in patients with SCC is not known. The possible influence of family history on survival in patients with SCC remains to be established. Linked Comment: Youlden and Baade. Br J Dermatol 2020; 183:414-415.
650    12
$a spinocelulární karcinom $x genetika $7 D002294
650    _2
$a epitelové buňky $7 D004847
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    12
$a sekundární malignity $x epidemiologie $x genetika $7 D016609
650    _2
$a rizikové faktory $7 D012307
650    12
$a nádory kůže $x genetika $7 D012878
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zheng, G $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Faculty of Medicine, University of Heidelberg, Heidelberg, Germany
700    1_
$a Hemminki, A $u Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
700    1_
$a Försti, A $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden
700    1_
$a Sundquist, K $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Japan
700    1_
$a Sundquist, J $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Japan
700    1_
$a Hemminki, K $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic
773    0_
$w MED00009371 $t The British journal of dermatology $x 1365-2133 $g Roč. 183, č. 3 (2020), s. 488-494
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31853941 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101758 $b ABA008
999    __
$a ok $b bmc $g 1690865 $s 1140606
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 183 $c 3 $d 488-494 $e 20200206 $i 1365-2133 $m British journal of dermatology $n Br J Dermatol $x MED00009371
GRA    __
$p Forskningsrådet om Hälsa, Arbetsliv och Välfärd $2 International
GRA    __
$p Helsingin ja Uudenmaan Sairaanhoitopiiri $2 International
GRA    __
$p Jane ja Aatos Erkon Säätiö $2 International
GRA    __
$p Deutsche Krebshilfe $2 International
GRA    __
$p Helsingin Yliopiston Tiedesäätiö $2 International
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace